Skip to main content
Fig. 3 | BMC Nephrology

Fig. 3

From: Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies

Fig. 3

Efficacy endpoints and cumulative probability of survival for the circuit. a Serious clotting rate (the primary outcome) in part one and part two trial. b The circuit survival time in each group. The median circuit survival time was 230 min (IQR 155 to 240) in the RCA-one group vs. 240 min (IQR 240 to 240) in the RCA-two group (P < 0.001); The median circuit survival time was 210 min (IQR 135 to 240) in the saline group vs. 240 min (IQR 240 to 240) in the RCA-two group (P = 0.003). c The Kaplan–Meier curves for uncensored circuit survival between the RCA-two and RCA-one groups. d The Kaplan–Meier curves for uncensored circuit survival between the RCA-two and Saline groups. The survival analyses were based on the log-rank test. Abbreviations: Saline, saline flushing group; RCA-two, two-stage regional citrate anticoagulation group; RCA-one, one-stage regional citrate anticoagulation group

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us